中国癌症研究(英文版)2024,Vol.36Issue(2) :195-214.DOI:10.21147/j.issn.1000-9604.2024.02.07

Circulating tumor DNA and its role in detection,prognosis and therapeutics of hepatocellular carcinoma

Sana Rashid Yingchuan Sun Umair Ali Khan Saddozai Sikandar Hayyat Muhammad Usman Munir Muhammad Usman Akbar Muhammad Babar Khawar Zhiguang Ren Xinying Ji Malik Ihsan Ullah Khan
中国癌症研究(英文版)2024,Vol.36Issue(2) :195-214.DOI:10.21147/j.issn.1000-9604.2024.02.07

Circulating tumor DNA and its role in detection,prognosis and therapeutics of hepatocellular carcinoma

Sana Rashid 1Yingchuan Sun 2Umair Ali Khan Saddozai 3Sikandar Hayyat 1Muhammad Usman Munir 4Muhammad Usman Akbar 5Muhammad Babar Khawar 6Zhiguang Ren 7Xinying Ji 8Malik Ihsan Ullah Khan1
扫码查看

作者信息

  • 1. Institute of Molecular Biology and Biotechnology,University of Lahore,Lahore 54590,Pakistan
  • 2. Department of Internal Oncology(Section Ⅰ),Xuchang Municipal Central Hospital,Xuchang 461000,China
  • 3. Institute of Translational Medicine,Medical College,Yangzhou University,Yangzhou 225001,China
  • 4. Australian Institute for Bioengineering & Nanotechnology,the University of Queensland,Brisbane 4072,Australia
  • 5. Gomal Center of Biochemistry and Biotechnology,Gomal University,Dera Ismail Khan 29111,Pakistan
  • 6. Institute of Molecular Biology and Biotechnology,University of Lahore,Lahore 54590,Pakistan;Applied Molecular Biology and Biomedicine Lab,Department of Zoology,University of Narowal,Narowal Punjab 51600,Pakistan
  • 7. Kaifeng Municipal Key Laboratory for Infection and Biosafety,Henan International Joint Laboratory of Nuclear Protein Regulation,School of Basic Medical Sciences,Henan University,Kaifeng 475004,China
  • 8. Faculty of Basic Medical Subjects,Shu-Qing Medical College of Zhengzhou,Zhengzhou 450064,China;Department of Medicine,Huaxian County People's Hospital,Huaxian 456400,China
  • 折叠

Abstract

Hepatocellular carcinoma(HCC)is considered the fifth most prevalent cancer among all types of cancers and has the third most morbidity value.It has the most frequent duplication time and a high recurrence rate.Recently,the most unique technique used is liquid biopsies,which carry many markers;the most prominent is circulating tumor DNA(ctDNA).Varied methods are used to investigate ctDNA,including various forms of polymerase chain reaction(PCR)[emulsion PCR(ePCR),digital PCR(dPCR),and bead,emulsion,amplification,magnetic(BEAMing)PCR].Hence ctDNA is being recognized as a potential biomarker that permits early cancer detection,treatment monitoring,and predictive data on tumor burden are subjective to therapy or surgery.Numerous ctDNA biomarkers have been investigated based on their alterations such as 1)single nucleotide variations(either insertion or deletion of a nucleotide)markers including TP53,KRAS,and CCND1;2)copy number variations which include markers such as CDK6,EFGR,MYC and BRAF;3)DNA methylation(RASSF1A,SEPT9,KMT2C and CCNA2);4)homozygous mutation includes ctDNA markers as CDKN2A,AXIN1;and 5)gain or loss of function of the genes,particularly for HCC.Various researchers have conducted many studies and gotten fruitful results.Still,there are some drawbacks to ctDNA namely low quantity,fragment heterogeneity,less stability,limited mutant copies and standards,and differential sensitivity.However,plenty of investigations demonstrate ctDNA's significance as a polyvalent biomarker for cancer and can be viewed as a future diagnostic,prognostic and therapeutic agent.This article overviews many conditions in genetic changes linked to the onset and development of HCC,such as dysregulated signaling pathways,somatic mutations,single-nucleotide polymorphisms,and genomic instability.Additionally,efforts are also made to develop treatments for HCC that are molecularly targeted and to unravel some of the genetic pathways that facilitate its early identification.

Key words

Hepatocellular carcinoma/circulating tumor DNA/biomarkers/single nucleotide variations/diagnosis/prognosis

引用本文复制引用

基金项目

国家自然科学基金(31902287)

Key Research and Development and Promotion Projects of Henan Province(242102310467)

Key Research and Development and Promotion Projects of Henan Province(242102310240)

Key Research and Development and Promotion Projects of Henan Province(232102310132)

Henan Department of Public Health(LHGJ20221021)

出版年

2024
中国癌症研究(英文版)
中国抗癌协会 北京市肿瘤研究所

中国癌症研究(英文版)

CSTPCD
影响因子:1.592
ISSN:1000-9604
参考文献量84
段落导航相关论文